Healthcare Global Enterprises Limited

rs,

Mumbai - 400051, Maharashtra, India BSE Limited, Compliance Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400001, Maharashtra, India Dear Sir/Madam, Subject : Investor Presenta

INR 51.4 Crore

ment ❖ Revenue from operations of HCG NCHRI LLP for the financial year ended March 31, 2023, was INR 51.4 Crores ABOUT THE TRANSACTION ❖ The company entered into Share Purchase agreement with shareholders of N

100%

iation oncology • First & #1 Comprehensive Cancer Center in private space in Indore • To acquire 100% of hospital on a slump sale basis Strategic Rationale • New Market Entry: Entering a key non-metr

20%

ritable hospital present for Oncology • Attractive market: Oncology market estimated to grow at 15-20% CAGR • Capacity Expansion: Capacity expansion by 100 beds at a nearby location, estimated to be

25%

centration Outcome • #1 player in market • Strong multi-modal clinical practice • Built a CoE • 25%+ EBITDA margin • #1 player in market • Comprehensive cancer care • Deployed latest technology fa

3x

trengthened radiation and medical oncology clinical talent • Diversified doctor revenue mix • 3x capacity addition (1) HMS (multispecialty) was acquired in 2007 but the comprehensive cancer care

13%

ellowship Programs is 26 7 www . h c g e l . c o m Financial Highlights Q1 FY24 R E V E N U E +13% 4,081 4,607 R E V E N U E - H C G C e n t e r s ( 1 ) R E V E N U E - M i l a n n C e n t e r s

14%

,081 4,607 R E V E N U E - H C G C e n t e r s ( 1 ) R E V E N U E - M i l a n n C e n t e r s +14% 4,443 3,908 -5% 173 164 Q1FY23 Q1FY24 Q1 FY23 Q1 FY24 Q1FY23 Q1FY24 E B I T D A * E B

5%

N U E - H C G C e n t e r s ( 1 ) R E V E N U E - M i l a n n C e n t e r s +14% 4,443 3,908 -5% 173 164 Q1FY23 Q1FY24 Q1 FY23 Q1 FY24 Q1FY23 Q1FY24 E B I T D A * E B I T D A * M A R G I

117 bps

r e - I N D A S ) P R O F I T A F T E R T A X ( P o s t - I N D A S ) +5% #Proforma EBIDTA - 117 bps 725 764 801 17.8% 16.6% +17% 110 94 +25% 76 61 Q1FY23 Q1FY24 Q1FY24# Q1FY23 Q1FY24

17.8%

F I T A F T E R T A X ( P o s t - I N D A S ) +5% #Proforma EBIDTA - 117 bps 725 764 801 17.8% 16.6% +17% 110 94 +25% 76 61 Q1FY23 Q1FY24 Q1FY24# Q1FY23 Q1FY24 Q1FY23 Q1FY24 Q1FY2

16.6%

A F T E R T A X ( P o s t - I N D A S ) +5% #Proforma EBIDTA - 117 bps 725 764 801 17.8% 16.6% +17% 110 94 +25% 76 61 Q1FY23 Q1FY24 Q1FY24# Q1FY23 Q1FY24 Q1FY23 Q1FY24 Q1FY23 Q1FY

“Although the Company believes that such forward‐looking statements are based on reasonable assumptions, it can give no assurance that such expectations will be met.”

“No Particulars Capex incurred till 30 th June 2023 Expected Capex for FY24 Total Planned Capex Expected date of Operations 1 2 Ahmedabad – Phase II Whitefield (Extension of Bangalore - COE) 180 10 628 150 852 250 Q1 FY25 Q3 FY25 1.”

Subject

1

Reference

1

Research and Academics

1

Reference

Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”) We wish to inform you that the Board of Directors of the Company, at their meeting held on August 10, 2023, inter alia, has approved the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2023 (“Financial Results”). In this respect, we enclose herewith the Presentation on the Financial Results of the Company for the quarter ended June 30, 2023. Request you to take this on record. Thanking you, For HealthCare Global Enterprises Limited Sunu Manuel Company Secretary & Compliance Officer Encl: a/a. HealthCare Global Enterprises Limited HCG Tower, # 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bangalore - 560027. 080 33669999 | info@hcgoncology.com | www.hcgoncology.com | CIN : L15200KA1998PLC023489 HEALTHCARE GLOBAL ENTERPRISES LIMITED I NV ESTOR P RESENTATI ON August 2023 SAFE HARBOR This presentatio

Research and Academics

❖ Total No of students ~290 ❖ Total Courses 44 ❖ Total allied health programs ~4 ❖ Total Nursing Programs is 5 ❖ Total DNB Programs is 7 ❖ Total DNB students is 70 ❖ Total Fellowship Programs is 26 7 www . h c g e l . c o m Financial Highlights Q1 FY24 R E V E N U E +13% 4,081 4,607 R E V E N U E - H C G C e n t e r s ( 1 ) R E V E N U E - M i l a n n C e n t e r s +14% 4,443 3,908 -5% 173 164 Q1FY23 Q1FY24 Q1 FY23 Q1 FY24 Q1FY23 Q1FY24 E B I T D A * E B I T D A * M A R G I N P R O F I T A F T E R T A X ( P r e - I N D A S ) P R O F I T A F T E R T A X ( P o s t - I N D A S ) +5% #Proforma EBIDTA - 117 bps 725 764 801 17.8% 16.6% +17% 110 94 +25% 76 61 Q1FY23 Q1FY24 Q1FY24# Q1FY23 Q1FY24 Q1FY23 Q1FY24 Q1FY23 Q1FY24 *EBIDTA excludes ESOP #Proforma EBIDTA had these acquisitions would have been done in Q1FY24 1. 22 comprehensive cancer centers, 3 multispecialty hospitals Rs in M n www . h c g e l . c o m 8 Improved Performance Leading to Profitability Revenue (INR mn) 1935 2479 2740 2981